NanoViricides (NNVC) is trading at $1.55 (up 6%) after Noble Capital Markets initiated coverage with an "Outperform" rating and a $6.00 price target. The report reviewed the company's lead broad-spectrum antiviral candidate NV-387, which is advancing toward Phase II human clinical trials. Recent progress includes regulatory approval in the Democratic Republic of the Congo (DRC) for an Ebola Phase II trial and preparations for an Mpox Phase II trial with NV-387 oral gummies. These developments, highlighted in the analyst report, have bolstered investor confidence in the company's clinical pipeline.